Enterprise Value
-93.34M
Cash
180.9M
Avg Qtr Burn
-12.77M
Short % of Float
2.91%
Insider Ownership
0.88%
Institutional Own.
54.47%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BMS-986288 (Anti-CTLA-4 non-fucosylated Probody) Details Solid tumor/s, Colorectal cancer | Phase 2 Data readout | |
BMS-986249 (CTLA-4-directed Probody therapeutic) Details Cancer, Melanoma | Phase 1/2 Update | |
CX-904 (EGFRxCD3) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
CX-2029 (PDC directed against CD71) Details Non-small cell lung carcinoma, Head and neck squamous cell carcinoma, Cancer, Solid tumor/s | Failed Discontinued | |
Praluzatamab ravtansine (CX-2009) (anti-CD166) Details Cancer, HER2-expressing cancers, Breast cancer | Failed Discontinued | |
Pacmilimab (CX-072) + CX-2009 (PD-L1 Targeting Probody Immunotherapy + CD166 PDC) Details Cancer, Triple-negative breast cancer | Failed Discontinued |